JB Ashtin

We are JB Ashtin, a different kind of medical communications company. We have extensive experience integrating innovative thinking with scientific content development and strong project management to provide comprehensive communications support to the biopharmaceutical industry. Because we know that there is a patient at the center of everything we do, our work is incredibly meaningful to us. Our expertise, our experience, and the personal connections we create form the backbone of the services we offer. Over the past 25 years, our clients have consistently expressed their trust in us. This trust builds confidence. We are not simply a vendor. We have become a trusted partner that helps our clients rise above challenges, taking their products from clinical development through commercialization. We have a solid reputation for going beyond expectations to deliver the extraordinary. We pride ourselves on offering innovative approaches to identify unmet patient needs and raise clinicians’ awareness about methods of treating targeted diseases. What we do has a significant impact on everyone involved, as we help expedite the progress of treatments and medical innovations. Yes, we are passionate about our work. We are passionate about helping our clients’ products reach healthcare practitioners and the patients who need them. We are passionate about our culture of collaboration and good spirit. We are passionate about making a difference for people. And we’d love to make a difference in partnership with you.

Research into medical interventions for weight loss – including the GLP-1 and GIP receptor agonists like semaglutide and others – has skyrocketed over the last 5 years. The weight loss benefits these medications have shown are now woven into the general zeitgeist, so why is JB Ashtin so excited for more data at #OW2024? The impact of GIP/GLP-1 RA drugs on the brain, particularly on the system that governs motivated behaviors and reward processing, that’s why. Take the study below for example: the investigators reviewed the number of opioid overdoses and alcohol intoxications in patients with opioid or alcohol-use disorder and found that patients who received GLP-1/GIP receptor agonists experienced fewer overdoses or intoxications than patients who did not. Given the urgent need for innovative treatments in the addiction field – data like these could represent a potential breakthrough for many people struggling with substance abuse. Before heading off to #OW2024 this weekend, what do you think, will GLP-1 inhibition become the therapy of the century by helping to solve complex conditions like addiction and obesity? What’s next for these “wonder drugs”? https://lnkd.in/es-_9jmv #obesity #addiction #JBAshtin

For Lexi Cogswell, the commitment to professional growth is personal. Lexi has dedicated the last 15 years of her career to sharing scientific discoveries, learning about the latest technologies in medical content development, and helping teams understand their key stakeholders — but her work doesn't end there. She also volunteers as a patient advocate leader with Ovarian Cancer Research Alliance to gain an even deeper understanding of patient, caregiver, and provider needs. "This personal and professional immersion has provided me with experience across the full drug development lifecycle from candidate identification through post-market medical information requests." Keep it up, Lexi — you're an inspiration to us all! 🙌 #JBAshtin #MedComms #Science #Healthcare #MedicalIndustry #EmployeeSpotlight

During her aunt's 18-year fight with breast cancer, our CEO Joni Bradley saw what a difference emotional and financial support can make during treatment. https://lnkd.in/gK-chmvj Want to show your support during #BreastCancerAwarenessMonth? Visit the National Breast Cancer Foundation, Inc. for educational resources — and consider donating to The Pink Fund if you can. 💗

This year's JB Ashtin Summit marked our 25th anniversary (!) and, as always, it was a fantastic experience full of team-building, educational workshops, and collaboration. Bet you can't guess the commemorative gift we gave our team, but you'll find the answer on our blog — and here's a hint: 🐊 https://lnkd.in/gvfHGnc3 #JBAshtin #CompanyCulture #CompanySummit #TeamBuilding #MedComms

Early detection is the best way to fight breast cancer. On #NationalMammographyDay, we encourage you to schedule a mammogram or encourage your loved ones to do so. It can make all the difference. 🩷 #BreastCancer #CancerPrevention #MedNews

What our clients say: "The beauty of JB Ashtin is they have just outstanding scientific knowledge." – VP of Medical Affairs, Pharmaceutical Client

During our recent Lunch & Learn session, we dove into all things AI — namely, how to monitor, regulate, and integrate generative AI for best results. Key takeaway? "At the end of the day, you're the expert." We believe in using AI to complement our creativity and output — not replace our critical thinking. #AI #JBAshtin #MedComms #GenerativeAI

We announced not one but THREE promotions during our annual summit: 👏 Lauren Rautiola Promoted to Executive Account Director 👏 Jay Parekh, PharmD, CMPP Promoted to Associate Scientific Director 👏 Jessica Miller Promoted to Senior Account Manager Can't wait to see what these incredible team players accomplish in their new roles. The future is bright at JB Ashtin! #Promoted #CompanySummit #JBAshtin

The sooner healthcare providers are informed of potential new therapies, the sooner they can help improve patient care. Artificial Intelligence (AI) has the potential for speeding up the dissemination of clinical trial results to the medical community by assisting in the development of medical journal articles. But, in its early stage is AI too good to be true?   Presumably, AI models have access to the medical literature from which it can draw from. But how does AI get access to full articles behind a pay wall? And how does AI “know” what potential references are good science and which ones are bad?   Clinical trial investigators typically have vast experience in treating patients within a therapeutic area or with a particular disease. They rely on this experience when placing the results of a clinical trial within the context of current standard of care and potential new therapies. Without this medical practice experience, how does AI correctly identify the nuances of treating a disease?   To create content, AI uses its model and paraphrases sources to which it has access. AI often paraphrases with authority and without citing its sources. Couldn't paraphrasing lead to unintentional plagiarism? Is AI able to apply Good Publication Practices?   All these questions point to the continued need for investigators to drive the final content to ensure appropriateness and scientific accuracy and ensure adherence to good publication practices and ethical writing standards. https://lnkd.in/gjqbjHew